A neoantigen long peptide dendritic cell vaccine combined with anti-CD38 antibody successfully suppressed immunotherapy-resistant 'cold' lung tumors in mice by depleting regulatory T cells.
25 of 132 peptides immunogenicBut only long peptide DC vaccination combined with anti-CD38 successfully suppressed cold tumor growth by depleting regulatory T cells
What the researchers found
From 2,536 missense mutations in the LLC1 lung cancer cell line, researchers identified 132 candidate neoantigen peptides, of which 25 induced CD8+ T cell responses. Short peptides failed to inhibit tumor growth as vaccines, but long peptide (L82)-pulsed dendritic cells delayed tumor growth in vivo. Combining L82-pulsed DC vaccination with anti-CD38 antibody effectively suppressed tumor growth by decreasing regulatory T cells in the tumor microenvironment, converting an immunotherapy-resistant cold tumor into one susceptible to immune rejection.
Why it matters
Roughly half of cancer patients don't respond to immunotherapy because their tumors are immunologically 'cold.' Finding ways to convert cold tumors into hot ones is one of the biggest challenges in oncology. This study demonstrates that a personalized neoantigen peptide vaccine combined with targeted antibody therapy can achieve this conversion, offering a potential strategy for treatment-resistant cancers.
The numbers in context
2,536 mutations; 132 candidate peptides; 25 CD8+ reactive; L82 long peptide delayed growth; anti-CD38 combo suppressed tumors; regulatory T cells decreased
How the study worked
Whole-exome and RNA sequencing of the LLC1 cell line identified neoantigen candidates. 132 short peptides were screened for immunogenicity, and 25 induced CD8+ T cell responses. Dendritic cells were pulsed with long peptides and tested as vaccines in mice bearing LLC1 tumors. RNA-Seq identified high CD38 expression on tumor cells, leading to combination treatment with anti-CD38 antibody. Tumor growth, T cell responses, and tumor-infiltrating lymphocyte composition were assessed.
Who was studied
LLC1 cold lung tumor mouse model treated with neoantigen DC vaccine and anti-CD38 antibody
What this study cannot tell us
This is a mouse study using a single lung cancer cell line (LLC1), limiting generalizability. Only one of the tested long peptides (L82) was effective as a vaccine. The approach requires tumor sequencing, neoantigen prediction, and combination therapy, making clinical implementation complex and expensive. Sample sizes for the animal experiments were not specified in the abstract.
How to read the evidence
This is a preclinical mouse study using a single tumor model. While the results are mechanistically convincing with multiple lines of evidence, translation to human cancers requires clinical trials with the inherent complexities of human tumor heterogeneity.
When this study was published
Published in 2021, this study is relatively recent and contributes to the active field of personalized cancer vaccines and combination immunotherapy strategies.
The bigger picture
Personalized cancer vaccines are a rapidly advancing field. This study shows that even immunotherapy-resistant tumors can be made vulnerable through the right combination of neoantigen peptide vaccines and antibody therapy. As sequencing costs drop and neoantigen prediction improves, approaches like this could become increasingly practical for patients who currently have no effective immunotherapy options.
Questions still open
- Can this neoantigen long peptide plus anti-CD38 approach be extended to other cold tumor types in humans?
- What makes long peptides more effective than short peptides for anti-tumor vaccination in this model?
- Could the approach be simplified enough for practical clinical implementation at scale?
Common questions
What are 'cold' tumors and why are they hard to treat?
Why did long peptides work better than short peptides as a cancer vaccine?
Read the original research
Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1.
Cancers, 13(21)
Citation
Sun, Changbo; Nagaoka, Koji; Kobayashi, Yukari; Nakagawa, Hidewaki; Kakimi, Kazuhiro; Nakajima, Jun. (2021). Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1.. Cancers, 13(21). https://doi.org/10.3390/cancers13215508